FDA Approves GSK’s PENMENVY 5-in-1 Meningococcal Vaccine GSK plc (LSE/NYSE: GSK) has announced that the U.S. Food and Drug Administration (FDA) has approved its PENMENVY vaccine (Meningococcal Groups A, B,…
MED-EL USA Gets FDA Approval for SONNET 3 Audio Processor MED-EL USA has announced the U.S. Food and Drug Administration (FDA) approval of its latest innovation, the SONNET 3 audio…
UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response UroGen Pharma Ltd. (Nasdaq: URGN) announced results from subgroup analyses of the pivotal ENVISION study, assessing the impact…
DaVita Inc. Q4 2024 Results DaVita Inc. (NYSE: DVA), a leading provider of dialysis services, has announced its financial and operational results for the fourth quarter and year ended December…
GE HealthCare Announces Q4 and Full Year 2024 Financial Results GE HealthCare (Nasdaq: GEHC) reported its financial results for the fourth quarter and full year ended December 31, 2024, showing…
Futibatinib Now Available in Italy for Cholangiocarcinoma Treatment, Announces Taiho Oncology Europe Taiho Oncology Europe GmbH has announced the availability of futibatinib in Italy for the treatment of cholangiocarcinoma (CCA),…
Incyte Reports Q4 and Year-End 2024 Results, Provides 2025 Financial Outlook and R&D Milestones Incyte (Nasdaq: INCY) has announced its financial results for the fourth quarter and full year ended…
Synedgen Appoints Dr. Laura Saward as Chief Scientific Officer Synedgen, Inc., a biotechnology company focused on glycobiology to treat gastrointestinal diseases, has appointed Dr. Laura Saward, PhD, as its Chief…
Cotiviti to Acquire Edifecs in Strategic Deal Cotiviti, a leader in data-driven healthcare solutions, has announced an agreement to acquire Edifecs, a trailblazer in healthcare data interoperability. This strategic acquisition…
Cancer Center Welcomes RefleXion’s SCINTIX Therapy with First Installation at BHCC RefleXion Medical, a leader in theranostic oncology, has announced that its RefleXion® X1 platform, featuring SCINTIX® biology-guided radiotherapy, will…
McKesson Reports Q3 Fiscal 2025 Results, Raises Full-Year EPS Guidance McKesson Corporation (NYSE: MCK) announced its third-quarter results for the fiscal year 2025, showing strong growth across various segments. The…
Amplar Health to Provide Hotel-Based Transition Care in South Australia For the first time in South Australia, a city hotel will provide an innovative new location for hospital patients who…